|Bid||8.11 x 1800|
|Ask||8.12 x 1100|
|Day's Range||7.72 - 8.40|
|52 Week Range||4.16 - 20.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The direct benefit for electroCore, Inc. (NASDAQ:ECOR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
If you want to know who really controls electroCore Inc (NASDAQ:ECOR), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in biggerRead More...
This week, there are a whopping eight biotech companies going public. Biotechnology isn’t an easy sector to grasp — it takes dedication to understand investment thesis, beginning the journey from drug development and ending at the drugstore. When it comes to investing in biotech stocks, the question is not just how well is this business run but whether their products fulfill a need in a growing industry … for biotechs, this can get complicated.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Eidos Therapeutics, Inc. (NASDAQ: EIDX ) will issue 6.25 million shares between $15 and $17 Wednesday on the Nasdaq. The ...